Physician profile
Alexander Mora
NPI 1225111941
$18,110.25
in general payments reported to CMS, 2019-2025
70 companies · $2,923 in 2025
The $2,923 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,276 · 2020: $2,294 · 2021: $2,438 · 2022: $2,501 · 2023: $2,642 · 2024: $3,037 · 2025: $2,923.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,589 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,589.32 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,793.93 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $1,685.11 | 2020-2025 | |
| Supernus Pharmaceuticals, INC. | $1,024.42 | 2019-2025 | Qelbree, Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $971.36 | 2021-2025 | Caplyta |
| Amgen INC. | $854.02 | 2019-2025 | Otezla, Repatha, Repatha |
| Lilly USA, LLC | $796.90 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Allergan, INC. | $725.90 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $669.57 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $654.47 | 2019-2024 | Xarelto, Invega Sustenna, Invega Trinza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $616.17 | 2020-2025 | Cycloset, Xifaxan |
| Sunovion Pharmaceuticals INC. | $512.49 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $481.19 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $479.93 | 2019-2024 | Austedo Xr, Austedo |
| Axsome Therapeutics, INC. | $455.34 | 2022-2025 | Auvelity, Sunosi |
| Lundbeck LLC | $401.89 | 2022-2025 | Abilify Asimtufii, Vyepti, Rexulti |
Show all 70 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Mora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.